Considering aesthetic surgery? You need to do your research and become an informed consumer.

Home

Search

Article Archive

Resources / Links

Aesthetic Surgery Books

Skin Care Store

Free Newsletter

FDA Approves Captique -- a New Non-Animal Stabilized Hyaluronic Acid Dermal Filler to Be Marketed by Inamed for Facial Wrinkle Correction

-- Captique(TM) Expands Inamed's Dermal Filler Portfolio for Facial Wrinkle Treatments

-- Captique is the Newest Dermal Filler Entry to the U.S. Market Based on Genzyme's Proprietary Non-Animal Stabilized Hyaluronic Acid Technology

(press release from Inamed Corporation @ Genzyme Corporation)

Buy PREVAGE Here!! Contains idebenone; the most potent antioxidant known for skin today. Reduces fine lines, smooths skin texture and protects skin cells from deterioration.

Inamed Corporation (Nasdaq:IMDC) and Genzyme Corporation (Nasdaq:GENZ) announced today that the U.S. Food and Drug Administration (FDA) has granted market approval for Captique(TM) Injectable gel -- a new dermal filler product based on Genzyme's non-animal stabilized hyaluronic acid (HA) technology.

Captique is the newest hyaluronic acid entry into the U.S. dermal filler marketplace. It is indicated for the correction of moderate to severe facial wrinkles and is manufactured by Genzyme. Inamed is Genzyme's exclusive U.S. marketing and distribution partner for Captique.

"We are excited with the FDA's approval of Captique, our initial non-animal stabilized hyaluronic acid-based dermal filler product in the U.S.," said Hani Zeini, Executive Vice President, Inamed Aesthetics. "This is the first of our non-animal stabilized HA pipeline products and an excellent complement to our existing Hylaform(R) and Hylaform(R) Plus product line in the U.S. This addition provides an expanded product portfolio for our physicians and their patients as they customize treatment options, and will strengthen our position in the aesthetics marketplace."

Inamed continues to be the only company that can offer physicians the broadest array of facial aesthetics products which allows them to create individualized and combination treatments for wrinkle correction. Captique joins Inamed's well-established U.S. dermal filler product franchise, comprised of Zyderm(R), Zyplast(R), CosmoDerm(R), and CosmoPlast(R) collagen and Hylaform(R) and Hylaform(R) Plus HA dermal fillers.

"We are pleased about the approval of Captique, our first non-animal stabilized hyaluronic acid dermal filler, and look forward to working with Inamed which will bring Captique to physicians and patients in the United States," said Ann Merrifield, President, Genzyme Biosurgery.

About Inamed Corporation

Inamed (Nasdaq:IMDC) is a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products that enhance the quality of people's lives. Inamed's current product portfolio is focused on the areas of facial aesthetics, breast aesthetics and obesity intervention. Inamed's Aesthetics division is a leader in the facial aesthetics and plastic surgery markets around the world. As the only global company whose facial portfolio and pipeline includes collagen-based dermal fillers, hyaluronic acid-based dermal fillers and botulinum toxin type A products, Inamed is well positioned to continue offering medical professionals and patients, now and into the future, the most comprehensive array of high-quality and innovative products for facial rejuvenation. The company's website is: www.Inamed.com

About Genzyme Corporation

Genzyme Corporation (Nasdaq:GENZ) is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. Genzyme's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services. Genzyme's commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. Over 7,000 Genzyme employees in offices around the globe serve patients in more than 80 countries.

Captique is the newest addition in the series of hyaluronic acid-based products developed by Genzyme. Genzyme leadership in biomaterials is built upon nearly two decades of pioneering work in the application of hyaluronic acid (HA) for medical and surgical uses.

Forward-Looking Statements

This press release contains forward-looking statements as of December 2, 2004, including statements regarding the estimated launch of Captique and the development and growth of Inamed's and Genzyme's product portfolios. These statements are based on the current intentions, beliefs and expectations of Inamed and Genzyme, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the actual timing for product shipment in the U.S., the results of research and development and business development activities, competition from existing and/or new products, market acceptance of the companies' products, the ability to manufacture or otherwise source product to meet market demand, the content and timing of decisions by the FDA, and the factors discussed under the captions "Factors Affecting Future Operating Results" in Genzyme's Quarterly Report on Form 10-Q for the Quarter ended September 30, 2004 and "Risks and Uncertainties" in Inamed's Annual Report on Form 10-K for the year ended December 31, 2003. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release and neither Inamed nor Genzyme undertakes any obligation to update or revise the statements. By disclosing any information in this press release, neither Inamed nor Genzyme is acknowledging that such disclosure is required by law or that such information is material.

Genzyme(R) and Hylaform(R) are registered trademarks, and Captique(TM) is a trademark of Genzyme Corporation. Zyderm(R), Zyplast(R), CosmoDerm(R), and CosmoPlast(R) are registered trademarks of Inamed Corporation. All rights reserved.

Contacts

Inamed
Dan Cohen, 202-638-4179 (Investors)
Michael Echter, 212-468-3188 (Media)
or
Genzyme
Sally Curley, 617-768-6140 (Investors)
Maria Foley, 617-768-6690 (Media)

Knowledge is Power. Information is How You Get It!

PROACTIV SOLUTION ACNE TREATMENT

HYLEXIN

ZENO